News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Reckitt Benckiser Plc (RB.L) Heroin-Abuse Drug Seen Luring Shire plc, Other Bidders


10/31/2013 7:36:31 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Reckitt Benckiser Group Plc’s heroin addiction treatment could tempt drugmakers from Shire Plc to Actavis Plc to bid for the company’s pharmaceuticals unit. Shire has been on the hunt for deals to ease reliance on its best-seller Vyvanse for attention deficit hyperactivity disorder. The Dublin-based drugmaker could be a logical buyer for the unit because it has managed competition with generics before and is adept at handling complex U.S. rules to curb illicit use of prescription medicines, Liberum Capital Ltd. said.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg

comments powered by Disqus
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES